Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study
View/ Open
Publication Date
2018Author
Abudho, O Bernard, Eric M. Ndombi,1,3 Bernard Guya,2 Jennifer M. Carter,4 Diana K. Riner,4 Nupur Kittur,4 Diana M. S. Karanja,1 W. Evan Secor,5 and Daniel G. Colley
Metadata
Show full item recordAbstract/ Overview
Schistosomiasis remains a major public health problem in Kenya. The World Health Organization recommends preventive chemotherapy with praziquantel (PZQ) to control morbidity due to schistosomiasis. Morbidity is
considered linked to intensity of infection, which along with prevalence is used to determine the frequency of mass drug
administration (MDA) to school-age children. We determined the impact of annual school-based MDA on children across
all primary and high school years using a repeated cross-sectional study design in five schools near Lake Victoria in
western Kenya, an area endemic for Schistosoma mansoni. At baseline and for the following four consecutive years,
between 897 and 1,440 school children in Grades 1–12 were enrolled and evaluated by Kato-Katz for S. mansoni and soiltransmitted helminths (STH), followed by annual MDA with PZQ and albendazole. Four annual rounds of MDA with PZQ
were associated with reduced S. mansoni prevalence in all school children (44.7–14.0%; P < 0.001) and mean intensity of
infection by 91% (90.4 to 8.1 eggs per gram [epg] of stool; P < 0.001). Prevalence of high-intensity infection (³ 400 epg)
decreased from 6.8% at baseline to 0.3% by the end of the study. Soil-transmitted helminth infections, already low at
baseline, also decreased significantly over the years. In this high prevalence area, annual school-based MDA with high
coverage across all Grades (1–12) resulted in rapid and progressive declines in overall prevalence and intensity of
infection. This decrease was dramatic in regard to heavy infections in older school-attending children.